NRC Health reported second-quarter 2026 results with Total Recurring Contract Value (TRCV) rising 11% year-over-year to $151.9 million and total revenue of $35.4 million, up 4% from the prior year. GAAP net loss for the quarter was $3.3 million, while Adjusted Net Income was $6.9 million, corresponding to adjusted diluted earnings per share of $0.31. The company also declared a quarterly cash dividend of $0.16 per share payable October 9, 2026.
Financial Highlights
- Revenue: $35.4 million for the three months ended June 30, 2026, up 4% year-over-year.
- Total Recurring Contract Value (TRCV): $151.9 million, up 11% year-over-year.
- GAAP Net Loss: $(3.3) million for the quarter (represents -9% of revenue).
- Adjusted Net Income: $6.9 million for the quarter; Adjusted diluted earnings per share: $0.31 on 22.0 million diluted shares.
- Adjusted EBITDA: $9.4 million for the quarter, representing a 27% Adjusted EBITDA margin.
Business Highlights
- Continued commercialization of product innovations and execution in go-to-market and solutions delivery.
- Strong bookings performance for The Governance Institute—its best in seven years—positioning the company for a stronger second half of 2026.
- Management emphasized NRC Health’s three connected strengths: continuous consumer and patient insights, trusted strategic engagement with healthcare leaders, and enabling actions that improve outcomes.
- Board declared a quarterly cash dividend of $0.16 per share, payable October 9, 2026 to shareholders of record as of September 25, 2026.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.